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Gene expression profiling, used within the
existing framework of toxicologic assessment,
promises to advance signiﬁcantly the mecha-
nistic understanding and prediction of
adverse effects. To benefit fully from the
opportunities offered by gene expression pro-
ﬁling, we must ﬁrst understand the relation-
ships between changes in gene expression and
alterations in traditional toxicology parame-
ters. The process by which gene expression
changes are linked to changes in phenotype
has been termed “phenotypic anchoring”
(Cunningham et al. 2003; Paules 2003;
Schmidt 2003). This approach has been used
successfully to identify groups of genes whose
expression correlates with speciﬁc pathologic
changes during griseofulvin-induced chronic
liver injury (Gant et al. 2003), renal toxicity
(Amin et al. 2004), furan-mediated hepato-
toxicity (Hamadeh et al. 2004), and aceta-
minophen-induced hepatotoxicity (Heinloth
et al. 2004). In the present study we used
phenotypic anchoring, in conjunction with
gene ontology analysis, to define the tran-
scriptional program associated with the
response of the rodent uterus to a reference
estrogen and to identify groups of genes that
may drive speciﬁc histologic changes.
The immature mouse uterus is a major
estrogen-responsive organ and forms the
basis for a reference assay of estrogenic
activity of chemicals (Owens and Ashby
2002). The physiologic response of the
uterus to exogenous estrogens has been doc-
umented in detail (Clark and Mani 1994).
The immature mouse uterus is sensitive to
elevations in endogenous levels of 17β-estra-
diol (E2) that occur during puberty. E2
releases the immature uterus from quies-
cence and promotes cell proliferation and
differentiation. The initial effects of E2 are
rapid (4–6 hr) and involve the uptake of
ﬂuid resulting from hyperemia and vasodila-
tion of uterine capillaries, which causes the
uterus to swell. This phenomenon is termed
“water imbibition” and increases the avail-
ability of substrates and ions required for
growth. Another early event is an increase in
overall levels of mRNA and protein synthe-
sis. The uterus then enters a proliferative
phase that is responsible, at least in part, for
the large increase in uterine weight that
occurs 16–30 hr after E2 exposure. Later
responses mimic the changes in uterine
physiology that accompany the onset of
puberty and include alterations in the sur-
face of the luminal epithelia.
Although the events described above
have been characterized at the physiologic
level, little is known about how E2, acting
through the estrogen receptors ER-α and
ER-β, coordinates at the molecular level the
myriad cellular processes involved, despite
signiﬁcant progress in elucidating the mole-
cular mechanisms by which ERs regulate
gene expression in vitro (Hall et al. 2001;
McKenna and O’Malley 2002; Metivier
et al. 2003; Moggs and Orphanides 2001;
Moggs et al. 2003; Tremblay and Giguere
2002). Our data reveal the transcriptional
program associated with E2-induced uterine
growth. We show that E2 induces a tightly
coordinated transcriptional program that
regulates successive and interlinked cellular
processes during the uterotrophic response.
Moreover, by comparing changes in gene
expression with alterations in uterine weight
and histology, we have identiﬁed classes of
genes that may drive specific histologic
changes in the uterus, including fluid
uptake, coordinated cell division, and
remodeling of the luminal epithelial cell
layer in preparation for embryo implanta-
tion. Our data also provide novel insights
into how E2 initiates paracrine signaling
events, recruits immune and inﬂammatory
cells, increases mRNA and protein synthe-
sis, and suppresses apoptosis.
These data describe, at an unprecedented
level of detail, how E2 induces organ growth
and maturation and provide a paradigm for
understanding the mechanisms of action of
other nuclear receptors. Furthermore, this
study demonstrates that analysis of the tem-
poral associations between a chemically
induced transcriptional program and the
accompanying histologic changes can
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A major challenge in the emerging ﬁeld of toxicogenomics is to deﬁne the relationships between
chemically induced changes in gene expression and alterations in conventional toxicologic para-
meters such as clinical chemistry and histopathology. We have explored these relationships in
detail using the rodent uterotrophic assay as a model system. Gene expression levels, uterine
weights, and histologic parameters were analyzed 1, 2, 4, 8, 24, 48, and 72 hr after exposure to
the reference physiologic estrogen 17β-estradiol (E2). A multistep analysis method, involving
unsupervised hierarchical clustering followed by supervised gene ontology–driven clustering, was
used to define the transcriptional program associated with E2-induced uterine growth and to
identify groups of genes that may drive specific histologic changes in the uterus. This revealed
that uterine growth and maturation are preceded and accompanied by a complex, multistage
molecular program. The program begins with the induction of genes involved in transcriptional
regulation and signal transduction and is followed, sequentially, by the regulation of genes
involved in protein biosynthesis, cell proliferation, and epithelial cell differentiation.
Furthermore, we have identified genes with common molecular functions that may drive fluid
uptake, coordinated cell division, and remodeling of luminal epithelial cells. These data define
the mechanism by which an estrogen induces organ growth and tissue maturation, and demon-
strate that comparison of temporal changes in gene expression and conventional toxicology end
points can facilitate the phenotypic anchoring of toxicogenomic data. Key words: estrogen, gene
expression, microarray, phenotypic anchoring, uterus. Environ Health Perspect 112:1589–1606
(2004). doi:10.1289/txg.7345 available via http://dx.doi.org/ [Online 7 October 2004]
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supplemental.pdf)provide valuable insight into the relation-
ships between gene expression changes and
phenotypic alterations.
Materials and Methods
Animals
Female Alpk:ApfCD-1 mice (19–20 days
old), weighing no more than 14 g on
arrival in the laboratory, were obtained
from a barriered animal breeding unit
(AstraZeneca, Macclesﬁeld, Cheshire, UK).
The animals were housed five per cage in
solid-bottom cages and allowed to acclima-
tize for 24 hr. They were allowed RM1 diet
(Rat and Mouse No. 1; Special Diet
Services Ltd., Witham, Essex, UK) and
water ad libitum for the duration of the
study. All animal experimentation
described in this article was conducted in
accord with accepted standards (local and
national regulations) of humane animal
care. Group sizes of 10 animals were used
for the ﬁrst two of the three replicate stud-
ies. Five animals per group were used in the
third replicate study.
Uterotrophic Assays
The mice were given a single subcutaneous
injection of E2 (400 µg/kg) or arachis oil
(AO; vehicle control) using a dosing vol-
ume of 5 mL/kg body weight. A single
dose of E2 was used to avoid the complex
transcriptional program that may result
from the standard uterotrophic assay expo-
sure regime (i.e., repeated administration
on 3 consecutive days; Odum et al. 1997).
The relatively high dose level of 400 µg/kg
was chosen to ensure a sustained and sig-
nificant increase in blotted uterine weight
during the 72-hr sampling period
(Supplemental Data, Figure 1). No overt
toxicity was observed during the 72-hr
exposure to E2 (400 µg/kg). All animals
were terminated at the appropriate time
using an overdose of halothane (Concord
Pharmaceuticals Ltd., Essex, UK) followed
by cervical dislocation. Vaginal opening
was recorded, and the uterus was then
removed, trimmed free of fat, gently blot-
ted, and weighed. Blotted uterine weights
were analyzed by covariance with terminal
body weights (SAS Institute Inc. 1999).
Half of each left uterine horn was ﬁxed in
10% formol saline and processed to paraf-
ﬁn wax for histologic analysis (Odum et al.
1997). The mean thickness of the endome-
trial and epithelial cell layers, indicators of
cellular hypertrophy, were calculated based
on the assessment of 10 locations on hemo-
toxylin- and eosin-stained longitudinal
uterine sections for each animal. All hyper-
trophy data were assessed for statistical
significance by analysis of variance
(ANOVA). The remainder of the uterus
was snap frozen in liquid nitrogen and
stored at –70°C for RNA extraction.
Mitotic Index
The total number of mitotic ﬁgures in each
uterus section was counted, noting the tis-
sue location, and the area of the section
was measured using a KS400 image analy-
sis system (Imaging Associates, Bicester,
UK). The number of mitotic figures per
square millimeter was calculated, and the
frequency after administration of E2 was
compared with the frequency seen after the
administration of AO using an appropriate
statistical procedure. The number of
mitoses per square millimeter was consid-
ered by a fixed-effects ANOVA allowing
for treatment, time, and the treatment by
time interaction. Analyses were carried out
using the MIXED procedure in SAS, ver-
sion 8.2 (SAS Institute Inc. 1999).
Contrasts within the treatment by time
interaction provided estimates of differ-
ences in E2 and control response at each
time point. These were compared statisti-
cally using a two-sided Student t-test based
on the error mean square in the ANOVA.
Transcript Proﬁling and Data
Analysis
Three independent biologic replicates of the
entire time course study for E2-treated and
time-matched AO-treated groups of ani-
mals were used to generate transcript proﬁl-
ing data and for subsequent statistical
analysis. To minimize the effect of any
interanimal variability, total RNA was iso-
lated from the pooled uteri for each treat-
ment group (n = 10 in the ﬁrst two studies;
reduced to n = 5 for the last study because
of highly similar transcriptional responses
being obtained in replicate studies 1 and 2)
using RNeasy Midi kits (Qiagen Ltd.,
Crawley, West Sussex, UK). Biotin-
labeled complementary RNAs were synthe-
sized using the Enzo Bioarray HighYield
RNA transcript labeling kit and hybridized
to Affymetrix murine U74-Av2 GeneChips
as described previously (Zhu et al. 2001)
and in the Affymetrix GeneChip expression
analysis technical manual (Affymetrix, Inc.
2002). Probe arrays were scanned and the
intensities were averaged using Microarray
Analysis Suite 5.0 (Affymetrix, High
Wycombe, UK). The mean signal intensity
of each array was globally scaled to a target
signal value of 500. To select E2-responsive
genes, each gene was subjected to a
mixed-model ANOVA allowing for treat-
ment, time, and the treatment by time
interaction as fixed effects and replicate
study as a random effect. The use of
mixed ANOVA models for the analysis of
differential gene expression in microarray
experiments has been previously described
(Churchill 2004; Cui and Churchill 2003).
Analyses were carried out using the MIXED
procedure in SAS, version 8.2 (SAS
Institute Inc. 1999). Contrasts within the
treatment by time interaction provided esti-
mates of differences in E2 and control
response at each time point. These were
compared statistically using a two-sided
Student t-test based on the error mean
square in the ANOVA [Supplemental Data,
Table 1 (http://ehp.niehs.nih.gov/txg/
members/2004/7345/supplemental.pdf)].
Data for genes exhibiting signiﬁcant changes
in expression (p < 0.01, two-sided) at one or
more time points were then exported into
GeneSpring 6.0 (SiliconGenetics, Redwood
City, CA, USA), and a data transformation
(values < 0.01 set to 0.01) and per-chip
normalization (to the 50th percentile)
were applied. Genes that did not have a
Present detection call (Affymetrix) in any
of the 14 treatment groups were removed
from further analysis. Ratios of changes in
gene expression were then calculated by
normalizing each E2-treated sample to its
corresponding time-matched vehicle
(AO)-treated control. GeneChip data sets
for the three independent biologic repli-
cates were interpreted in log of ratio analy-
sis mode, with biologic replicates being
selected as a noncontinuous parameter. A
total of 3,538 E2-responsive genes exhibit-
ing a minimum of 1.5-fold up- or down-
regulation in at least one time point were
then subjected to gene tree–based hierar-
chical clustering (Pearson correlation). To
identify genes that function in speciﬁc bio-
logic pathways, these 3,538 genes were
further filtered using functional annota-
tions derived from the NetAffx database‚
Analysis Center (Liu et al. 2003; http://
www.affymetrix.com/analysis/index.affx),
together with manual annotations from
published literature, before hierarchical
clustering using GeneSpring. Gene names
used in this article (see Appendix) were
derived by homology searching of
nucleotide sequence databases (BLASTn;
http://www.ncbi.nih.gov/BLAST/) using
Affymetrix probe target sequences and the
interrogation of NetAffx (Liu et al. 2003)
database. All genes described in the ﬁgures
and text showed statistically significant
alterations in expression in all three
replicate studies. MIAME (Minimum
Information About a Microarray
Experiment)-compliant microarray data
for the three independent replicate studies
are available as supplementary information
and have been submitted to the Gene
Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geo/).
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Polymerase Chain Reaction
Uterine RNA was isolated and purified
from all E2-treated and time-matched vehi-
cle control groups (each consisting of
pooled uteri) in all three replicate time
course studies using the Qiagen RNeasy
Midi kit (Qiagen). Before reverse transcrip-
tion, RNA was treated with Dnase I
(DNA-free kit; Ambion, Huntington, UK)
to remove any contaminating genomic
DNA. For each pool, 2 µg total RNA was
reverse transcribed in a 25-µL reaction using
SuperScript II (Invitrogen, Paisley, UK) and
oligo-dT primer according to the manufac-
turer’s instructions. Polymerase chain reac-
tion (PCR; 25 µL) containing 2 µL
ﬁrst-strand cDNA (1:10 dilution), 12.5 µL
of SYBR Green PCR Master Mix (Applied
Biosystems, Warrington, UK), and 0.3 µM
each of forward and reverse primers were
run for 40 amplification cycles in an
ABI PRISM 7700 Sequence Detection
System (Applied Biosystems). Cycling con-
ditions were 50°C for 2 min, 9°C for
10 min, 95°C for 15 sec, and 60°C for
1 min. All reactions were run in triplicate.
Toxicogenomics | Uterotrophic transcriptional program
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Figure 1. Uterotrophic response to a single dose of E2. (A) Uterine blotted weight. Data for replicate studies A and B are mean ± SD from 10 immature female mice
in each treatment group. Five animals per group were used in replicate study C. (B) Temporal expression proﬁle of the estrogen-responsive genes complement
component C3 and C-FOS. Quantitative RT-PCR analysis of FOS and LTF gene expression from three independent time-course studies (A–C) and comparison with
microarray data. Each RT-PCR data point represents a fold value, obtained using the comparative Ct (threshold cycle) method, for E2-induced change in gene
expression relative to time-matched vehicle controls. The fold induction value is relative to the endogenous control gene RPB1 and to treatment, that is, estro-
gen/untreated. Microarray data are ratios (E2:time-matched vehicle control) of normalized Affymetrix GeneChip signal intensities (see Figure 3A and “Materials
and Methods”). 
*p < 0.05; **p < 0.01.
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CReal-time (RT) PCR primers for FOS (5´-
CTGTGGCCTCCCTGGATTTG-3´and
5´-TGAGAAGGGGCAGGGTGAAG-3´),
LTF (5´-CGGGGGCCTTCAGACCATC-
3´and 5´-CTAAAGTGACAGCAGGG
AGTG-3´), and the control gene RPB1
(5´-GTTCTGGACCCCATTTTT
GATAGGC-3´ and 5´-CAGGGGACTG-
GCAGGGTAACAA-3´) were designed
using Primer Express software (version 1.5;
Applied Biosystems) to generate amplicons
within their corresponding Affymetrix probe
set target sequences.
Results
Histologic Changes and Increases 
in Uterine Weight
Our aim was to identify the genes and mol-
ecular networks associated with the
uterotrophic response and to define the
relationships between gene expression
changes and histologic alterations. To this
end, we gave immature female mice a
single subcutaneous injection of E2
(400 µg/kg) or vehicle and used DNA
microarrays to measure uterine gene
expression profiles at seven different times
(1, 2, 4, 8, 24, 48, and 72 hr) after expo-
sure. To facilitate the phenotypic anchor-
ing of expression changes, we also
measured blotted uterine weights and
determined the average heights of the lumi-
nal epithelium and stromal endometrium
for each animal. Three independent repli-
cate experiments were carried out to allow
a rigorous statistical analysis of the gene
expression data (see “Materials and
Methods”). We chose to use a single dose
of E2 to avoid the complex transcriptional
program that may result from the standard
uterotrophic assay exposure regime in
which test compound is dosed by repeated
administration on 3 consecutive days
(Odum et al. 1997). This dose induced a
sustained increase in blotted uterine weight
that was similar in the three replicate
experiments (Figure 1A). In each replicate
experiment, a signiﬁcant increase (p < 0.01)
in uterine weight was observed 4 hr after
exposure to E2 and reached maximal levels
between 24 and 72 hr (Figure 1A).
Histologic analysis of uterine sections
revealed the cellular changes associated
with the increase in uterine weight between
1 and 72 hr (Figure 2A). Consistent with
previous reports (Clark and Mani 1994),
the weight increase that occurred within
4 hr of exposure (Figure 1A) was associated
with thickening of the stromal endo-
metrium (Figure 2B) resulting from the
uptake of fluid. The larger increase in
uterine weight that occurred between 8 and
24 hr was due to hypertrophy and cell pro-
liferation (Kaye et al. 1971; Quarmby and
Korach 1984), which caused an increase in
thickness of the luminal epithelium
between 8 and 24 hr (Figure 2C). We con-
clude that the single dose of E2 used
induced a conventional uterotrophic
response. Furthermore, the expression pro-
files of two classical E2-responsive genes,
lactotransferrin (LTF; Liu and Teng 1992)
and the proto-oncogene C-FOS (Weisz and
Bresciani 1988), demonstrate that E2
elicited a robust transcriptional response
that was similar in the three replicate
experiments (Figure 1B).
Multistep Method for Analysis 
of Gene Expression Changes
Uterine RNA from the seven time points for
each of the E2-treated and time-matched
vehicle control groups was analyzed using
Affymetrix MG-U74Av2 GeneChips. A
total of 42 microarray data sets were col-
lected for the three replicate experiments.
We used a multistep method to analyze the
microarray gene expression data (Figure 3A).
First, data were ﬁltered and subjected to sta-
tistical analyses to identify the 3,538 genes
with altered expression in E2-treated mice
(p < 0.01 and > 1.5-fold) during at least one
Toxicogenomics | Moggs et al.
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Figure 2. Histologic analysis of uterotrophic response to a single dose of E2. (A) Panels show longitudinal 0.3-µm–thick paraffin sections of uteri stained with
hematoxylin and eosin; bar = 50 µm. Luminal space (L), luminal epithelium (LE), stromal endothelium (SE), and glandular epithelium (GE) are indicated. (B) Height of
stromal endothelial cell layer. (C) Height of luminal epithelial cell layer. Data in B and C are mean ± SD from 10 immature female mice in each treatment group.
Solid bars, E2; open bars, AO.
*p < 0.05; **p < 0.01.
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Unsupervised hierarchical clustering was
then used to group these genes into co-
regulated clusters (Quackenbush 2002;
Figure 3B), revealing a complex multistage
transcriptional response to E2 in the uterus
(gene clusters A–I in Figure 3B). To gain an
overview of the predominant molecular
functions and biologic pathways that were
regulated at the transcriptional level during
the uterotrophic response to E2, we interro-
gated the 3,538 E2-responsive genes using
the GOStat gene ontology mining tool
(http://gostat.wehi.edu.au) (Beissbarth and
Speed 2004). This approach revealed
that E2 targets predominantly genes
involved in protein metabolism, cell cycle,
cell proliferation, DNA replication, RNA
metabolism, mRNA transcription, and
blood vessel development [Supplemental
Data, Table 2 (http://ehp.niehs.nih.gov/txg/
members/2004/7345/supplemental.pdf)].
Next, we used a supervised clustering
approach using customized gene ontology
deﬁnitions (see “Materials and Methods”) to
identify gene functions that were predomi-
nant in each co-regulated cluster in
Figure 3B. This revealed that E2 regulates
each class of gene during a narrow window
of time and suggests that E2 induces uterine
growth and maturation by regulating succes-
sively the activities of different biologic
pathways (described below). Finally, we ana-
lyzed the temporal associations between the
gene expression program and alterations in
uterine weight and histology to anchor the
gene expression changes to alterations in
uterine phenotype. These associations are
described below.
Phase 1: Rapid Induction of
Transcriptional Regulators and
Signaling Components by E2
The ﬁrst 4 hr of the uterotrophic response
is characterized by the influx into the
uterus of fluid that provides the nutrients
and ions required for growth (Clark and
Mani 1994). This leads to decompaction
of stromal cells (Figure 4A) and thickening
of the stromal endometrial layer at 4 hr
(Figure 2B). This first phase of the
uterotrophic response is accompanied by
the rapid and transient regulation of genes
encoding components of intra- and inter-
cellular signaling pathways (Figure 4B)
and sequence-specific transcriptional regu-
lators (Figure 4C). Most of these genes
show maximal expression between 1 and
4 hr, suggesting that the transcriptional
effects of E2, mediated via ER-α and
ER-β, are amplified rapidly through the
induction or modulation of multiple
transcriptional and nontranscriptional
signaling pathways.
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Figure 3. (A) Experimental strategy for phenotypic anchoring of E2-responsive genes during
uterotrophic response. Three independent biologic replicate studies were performed in which we ana-
lyzed seven different time points for E2-treated animals and the equivalent time points for vehicle-
treated animals. (B) Staged transcriptional response of the immature mouse uterus to E2. Gene tree
generated by hierarchical clustering of 3,538 E2-responsive genes showing clusters (labeled A–I) of
temporally co-regulated genes. The genes clustered in groups A–I are further annotated using gene
ontology analyses in Figures 4–7. The color scale indicates the mean fold change of E2-induced gene
expression relative to time-matched AO-treated control samples (based on the three independent stud-
ies shown in Figure 1A).Signaling Genes
The signaling genes rapidly up-regulated
by E2 function in a broad array of signal
transduction pathways (Figure 4B). These
genes include protein kinases (AKT,
MEK1, PIM3), growth factors (VEGF,
PLGF), GTPases (RHOC, RAB11A,
DEXRAS1), cytokine signaling proteins
(MCP1, SOCS1, SOCS3, WSB1, IL17R),
and a Wnt signaling factor (WNT4).
Several E2-induced genes may act to
attenuate initial signaling events (e.g., the
protein phosphatase MKP1 negatively
modulates MAP kinase activity). Strikingly,
many of the signaling genes induced within
4 hr of E2 exposure have roles in the regu-
lation of vascular permeability in other tis-
sues, suggesting that they may be involved
directly in initiating the inﬂux of ﬂuid into
the uterus at this time (Figure 4B). These
genes include angiogenic/vascular cell
growth factors (VEGF, PLGF, ADM,
ANGPT2, TGFB2), vasoactive serine pro-
teases (KLK2, KLK6, KLK9, KLK22), and
vascular endothelial receptors (IL17R,
BDKRB1, ENG, GNA13). Furthermore,
the vascular growth factor receptors TIE1
and TIE2 are rapidly down-regulated in
response to E2 (Figure 4B), which may
serve to attenuate the uptake of fluid after
4 hr. Collectively, these genes shed light on
the mechanism by which E2 promotes ﬂuid
uptake in the uterus and provide a clear
link between gene expression changes and
histologic changes occurring at this time.
Transcriptional Regulators
The sequence-specific transcription factors
induced during the first 4 hr of the
response can be divided into four main
classes (Figure 4C). The first contains
members of the Jun, Fos, and ATF sub-
groups of transcription factors (C-FOS,
FOSB, C-JUN, JUNB, ATF3, ATF4,
ATF5) that form AP-1 dimers implicated
in the regulation of cell proliferation and
survival (Shaulian and Karin 2001). The
second class contains genes that control cell
differentiation during the development of a
number of tissues (SOX11, SOX18, HEY1,
CART1, PRX2, SMAD7, ID1). The early
induction of members of this class suggests
that E2 deploys a diverse range of gene
expression networks to control cell growth
and differentiation in the uterus. The third
class contains two genes that encode co-
regulators for nuclear receptors (RIP140,
NCOR2), suggesting that these may act to
modulate ER-mediated responses to E2 in
the uterus. The fourth class of genes
encodes presumed transcriptional regula-
tors of unknown function (e.g., GIF).
We conclude that the initial response to
E2 serves to a) modulate the activities of
Toxicogenomics | Moggs et al.
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Figure 4. Phase 1: rapid induction of transcriptional regulators and signaling components by E2. (A) Water
imbibition and increased vascular activity in stromal endothelium (SE) 2 and 4 hr after a single dose of E2.
Longitudinal 0.3-µm–thick parafﬁn sections of uteri stained with hematoxylin and eosin are shown. Scale
bar, 50 µm. (B) Coordinate expression of genes encoding signaling components. Genes marked with a red
circle have functions associated with altered vascular permeability and may drive the water imbibition
seen at this time. (C) Coordinate expression of genes encoding transcription factors. Detailed quantitative
data for genes encoding AP-1 transcription factors are shown in Figure 8B. Gene trees were generated
by supervised hierarchical clustering; genes with related functions were selected from clusters of tempo-
rally co-regulated E2-responsive genes (Figure 3B) using universal gene ontology descriptions. The color
scale for fold change in expression is identical to that used in Figure 3B. Data derived from independent
Affymetrix probe sets are shown for GIF and SOX18. See Appendix for gene nomenclature and Affymetrix
probe sets.intra- and intercellular signaling pathways
that, among other functions, promote vas-
cular permeability and fluid uptake and
b) up-regulate the expression levels of tran-
scription factors that promote growth and
differentiation. These early gene expression
changes facilitate the amplification of the
originating hormonal signal and set into
motion the series of events that result in
uterine growth and differentiation.
Phase 2: Coordinated Induction 
of Genes Required for mRNA 
and Protein Synthesis
No increase in uterine weight or obvious
changes in uterine histology occur between
4 and 8 hr (Figures 1 and 2). Nevertheless,
our data reveal that this phase is associated
with the induction of a large cluster of
genes (Figure 5). Most are induced 2 hr
after E2 administration, reach maximal
expression at 4 or 8 hr, and return to
control or subcontrol levels by 48 hr
(Figure 5B). Most of these genes play roles
in mRNA and protein synthesis, demon-
strating that the bulk of transcriptional
activity occurring at this time functions to
increase the capacity of the uterus for new
protein synthesis. This is consistent with
earlier observations that exposure to E2
results in a rapid increase in the mRNA
and protein content of the uterus (Clark
and Mani 1994). Our data deﬁne the mol-
ecular basis for these prior observations and
identify the genes targeted by ERs to
induce these effects.
In a broad sense, protein synthesis
includes the interlinked processes of tran-
scription, mRNA processing, mRNA export
into the cytoplasm, protein translation, and
protein folding (Orphanides and Reinberg
2002, and references therein; Figure 5G).
Our data reveal the coordinated induction of
genes involved in each of these processes
(Figure 5A–F). These genes include a) com-
ponents of the RNAP II general transcrip-
tion machinery (RPB8, RPB10, TAF10;
Figure 5A); b) transcription termination and
polyadenylation factors (NSAP1; Figure 5A);
c) mRNA splicing factors (SFPQ, U2AF1,
RNPS1; Figure 5A); d) mRNA export pro-
teins (NXF1; Figure 5C); e) protein transla-
tion factors (EIF1A, EIF2A, EIF2B, EIF3;
ribosomal proteins RPL11, RPL12, RPL20,
RPL52, RPS18b, and tRNA synthetases
VALRS, GLURS, PHERS; Figure 5D), and
f ) protein folding factors (FKBP4, CCT3,
CCT6a, CCT7, CCT8; Figure 5E). The
down-regulation of several genes associated
with transcriptional repression (HDA1,
TGIF, MAD4, EZH1) and mRNA degrada-
tion (AUH; Figure 5B) may also contribute
to the general elevation of mRNA synthe-
sis. We also note a concurrent increase in
the expression of components of the ubiqui-
tin–proteasome proteolytic pathway (PAD1,
SUG1; Figure 5F) and genes whose prod-
ucts are required for the nuclear import
and export of proteins (IMPORTINα2,
IMPORTINα3, RAE1, G3BP2; Figure 5C),
indicating that E2 additionally elevates
proteasome levels and nuclear-cytoplasmic
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Transcriptional repression Figure 5. Phase 2: coordinated induction of genes required for mRNA and protein
synthesis. Coordinated expression of genes involved in (A) RNA synthesis,
(B) transcriptional repression, (C) nuclear import/export, (D) protein translation,
(E) protein folding, and (F) protein degradation. Gene trees were generated as
described in Figure 4. Data derived from independent Affymetrix probe sets are
shown for eIF1A, eRF1, and CCT3. See Appendix for gene nomenclature and
Affymetrix probe sets. (G) Schematic overview of RNA and protein synthesis in
eukaryotes, showing machinery involved in each step of the process. Reprinted
from Orphanides and Reinberg (2002), with permission from Elsevier.protein transport activity at this time. We
conclude that E2 is able to increase protein
synthesis activity in the uterus by altering the
expression of genes involved in all aspects of
the protein biosynthesis pathway.
Therefore, during the first two phases
of the transcriptional program, E2 induces
the expression of a battery of sequence-spe-
cific transcriptional regulators (phase 1;
Figure 4C) and then induces the expression
of genes in the protein synthesis pathway
(phase 2; Figure 5). It appears, therefore,
that, during phase 1, E2 specifies the gene
expression networks that will be active, and
then ensures during phase 2 that these net-
works have sufficient mRNA and protein
synthesis capacity to operate. In addition
the increased expression of components of
the RNA and protein synthesis machinery
is likely to be a prerequisite for prolifera-
tion in the uterus because cells must
increase their mass before division to pro-
vide sufficient cellular components
required for survival of the daughter cells
(Norbury and Nurse 1992). Consistent
with this, we note that induction of protein
synthesis components immediately pre-
cedes the up-regulation of genes required
for proliferation (Figure 6; see below). An
additional function of the increased uterine
capacity for protein synthesis may be to
facilitate the production of the abundant
cytoarchitectural and secreted proteins
induced at the end of the uterotrophic
response (see below).
Phase 3: Coordinated Regulation 
of Genes Controlling Chromosome
Replication and the Cell Cycle
The next phase in the uterotrophic response
occurs between 8 and 24 hr and involves an
approximate doubling in uterine weight
(Figure 1A) and a large increase in the
thickness of the luminal epithelium
(Figures 2C, 6A). A quantitative histologic
analysis of mitotic figures in the uterine
cells (“Materials and Methods”) revealed a
clear and statistically signiﬁcant (p < 0.01)
increase with E2 at 24 hr, whereas no
E2-dependent increase was observed at 8,
48, or 72 hr (Table 1, Figure 6A). These
observations are consistent with previous
studies showing that most cells in the
immature rodent uterus are stimulated to
leave their quiescent state and divide syn-
chronously under the inﬂuence of E2 (Kaye
et al. 1971; Quarmby and Korach 1984).
We found that genes required for the
replication of chromosomal DNA (PCNA,
FEN1, CDC6, MCM2, MCM3, MCM4,
MCM5, ORC1, ORC6, RRM1, RRM2) and
genes required for postreplicative phases of
the cell division cycle (e.g., CCNB1, PLK1)
are coordinately induced and reach maximal
expression levels between 8 and 24 hr
(Figure 6B), consistent with the timing of
the histologic changes observed in Figure 6A.
Genes required for maintaining genome
integrity (CHK1, CKS1, GEMININ) and the
epigenetic status of newly replicated DNA
(CAF-1 p60, AHCY) are also up-regulated at
8 and/or 24 hr (Figure 6B). It is striking that
after their induction during the proliferative
phase (8–24 hr), the expression levels of
most genes that regulate chromosome repli-
cation and cell division are reduced to levels
well below those of control animals
(Figure 6B). This suggests that mechanisms
exist for the active repression of these genes
to prevent further rounds of proliferation.
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Figure 6. Phase 3: coordinated regulation of genes controlling chromosome replication and the cell cycle.
(A) Thickening of luminal (LE) and glandular epithelium (GE) and increased number of mitotic cells (indi-
cated by arrowheads) between 8 and 24 hr after a single dose of E2. Longitudinal 0.3-µm–thick paraffin
sections of uteri were stained with hematoxylin and eosin. Scale bar, 50 µm. Coordinated expression of
genes involved in (B) chromosome replication and cell division, (C) cell-cycle regulation, (D) and apopto-
sis. Gene trees were generated as described in Figure 4. Data derived from independent Affymetrix probe
sets are shown for MCM3. See Appendix for gene nomenclature and Affymetrix probe sets.Declining E2 levels in mice 48 hr after a
single subcutaneous injection may also con-
tribute to the cessation of proliferation.
Together, these data provide a molecular
explanation for the changes in uterine
weight and histology that occur between 8
and 24 hr (Figures 1A, 2, and 6A) and sup-
port the assertion that the early increase in
weight seen at 4 hr is due to fluid uptake.
Furthermore, these gene expression changes
demonstrate that cell proliferation is
restricted to a narrow window of time
between 8 and 24 hr by the coordinated reg-
ulation of chromosome replication and cell
division genes.
Regulation of Cell Division
Our data also provide insight into the
mechanisms by which E2 releases cells of
the immature uterus from quiescence and
promotes cell division. The E2-induced
expression proﬁle of E2F1, a key transcrip-
tional regulator of DNA replication genes
(Ohtani 1999), closely parallels the induc-
tion of the chromosome replication genes
(Figure 6B), consistent with the proposal
that E2F1 regulates the expression of com-
ponents of the DNA replication fork in
human breast cancer cell lines exposed to
E2 (Lobenhofer et al. 2002). Our data indi-
cate that release from quiescence also
involves the E2-induced down-regulation
of genes that maintain cells in a growth-
arrested state (KIP1, CCNG2, CCNG1).
The principle way in which mitogens
induce proliferation of quiescent cells
involves a reduction in levels of the Kip1
protein, which inhibits the activities of
cyclin–cdk complexes and induces cell
cycle arrest (Olashaw and Pledger 2002).
We found that KIP1 was down-regulated
within 1 hr of E2 exposure and remains
repressed over a period of at least 24 hr,
only reaching control levels when cell
proliferation has ceased (Figure 6C).
Furthermore, E2 may promote degradation
of the Kip1 protein via the induction of
CDC34 (Figure 6C), a gene that has been
implicated in the ubiquitin-mediated
degradation of Kip1 (Koepp et al. 1999).
These data suggest that E2 promotes cell
proliferation by coordinately reducing
Kip1 mRNA and protein levels. It is not
clear whether KIP1 is a direct or indirect
target of the activated ERs. However, KIP1
gene expression is controlled by ras-medi-
ated PI3K signaling pathways (Olashaw
and Pledger 2002), components of which
are up-regulated rapidly in response to E2
(e.g., DEXRAS1, RASSF1; Figure 4B).
Suppression of Apoptosis
E2 protects against apoptosis in a number
of tissues, including brain, testes, and
uterus (Thompson 1994). Although the
anti-apoptotic activity of estrogen in the
uterus is thought to play a crucial role in
the maintenance of uterine homeostasis,
the mechanistic basis for this action has not
been defined. Our data reveal that E2
induces the expression of anti-apoptotic
genes (BAG2, BAG3, DAD1) while
simultaneously down-regulating the
expression of pro-apoptotic genes (CASP2,
NIX; Figure 6D). Thus, apoptosis appears
to be suppressed through transcriptional
mechanisms during E2-induced uterine
growth. Consistent with these observations,
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Table 1. Quantitative histologic analysis of mitotic
ﬁgures in uterine cells after exposure to E2 for 8,
24, 48, and 72 hr.a
Mitosis/mm2 (mean ± SD)
Time (hr) AO (5 mL) E2 (400 µg)
8 1.36 ± 1.81 0.51 ± 0.41
24 3.86 ± 5.05 25.15 ± 6.37**
48 3.81 ± 0.83 3.46 ± 3.26
72 3.88 ± 2.28 1.67 ± 1.77
Quantitative mitotic index data were derived from four
animals per group.
aData were assessed for statistical significance using
ANOVA and a two-sided Student t-test (see “Materials
and Methods”). **p < 0.01.
B A
D
Complement
Chemoattractant
cytokines Iron homeostasis
E C
1 2 4 8 24 48 72
Time (hr)
1 2 4 8 24 48 72
Time (hr)
Cytoarchitecture Defense responses
Figure 7. Phase 4: induction of genes involved in uterine cell differentiation and defense responses.
(A) Cytoarchitecture; (B) defense responses; (C) chemoattractant cytokines; (D) complement; and (E) iron
homeostasis. Gene trees were generated as described in Figure 4. Data derived from independent
Affymetrix probe sets are shown for SPRR2A, CD133, TROP2, BGP1, CLU, KRT19, and CFH. Detailed quanti-
tative data for the SPRR gene family are shown in Figure 8B. See Appendix for gene nomenclature and
Affymetrix probe sets.E2 also induces the apoptotic regulators
BCL2 and BAG1 in cultured breast cancer
cells (Perillo et al. 2000; Soulez and Parker
2001). It will be important to determine
whether estrogens elicit similar changes in
the expression of apoptosis-regulating
genes in other tissues.
Phase 4: Induction of Genes Involved
in Uterine Cell Differentiation 
and Defense Responses
The period from 24 to 72 hr after E2
exposure is associated with remodeling of
the luminal epithelial cell layer, including
the formation of secretory epithelial cells
and a glycocalyx layer consisting of glyco-
proteins (Paria et al. 2003; Weitlauf 1994).
These changes result in the formation of a
highly differentiated epithelial layer that is
primed for cell recognition and adhesion
events necessary for embryo attachment
and implantation.
Changes in Cytoarchitecture
The final phase of the uterotrophic
response coincides with the induction of a
battery of genes involved in the cytoarchi-
tectural remodeling of proliferating uterine
cells, thus providing a further link between
phenotypic and gene expression changes
(Figure 7A). These genes encode compo-
nents of desmosomes (DSG2), gap junc-
tions (CX26), tight junctions (CLDN4,
CLDN7), the corniﬁed envelope (SPRR1A,
2A, 2B, 2E, 2F, 2G, 2I, 2J), intermediate
filaments (KRT19), and a variety of cell-
surface and extracellular-matrix glyco-
proteins (SPP1, BGP1, BGP2, MUC1,
TROP2, CLU). The latter class of genes is
likely to contribute to the formation of the
glycocalyx layer present on differentiated
uterine epithelium (Weitlauf 1994). The
concomitant E2-dependent induction of a
number of enzymes required for carbohy-
drate metabolism (MAN2B1, GALNT3)
may provide the increase in sugar metabo-
lism necessary for the production of these
glycoproteins. E2 also induces genes encod-
ing ion channels that regulate the balance
of Na+ absorption and Cl– secretion across
the endometrial epithelium to maintain a
luminal fluid microenvironment suitable
for implantation (CFTR, CLCA3, MAT8;
Figure 7A).
Defense Responses
A number of genes involved in host defense
processes or detoxiﬁcation are ﬁrst regulated
between 24 and 72 hr (Figure 7B).
We speculate that the products of these
genes may provide an environment that is
protective of, and facilitates, embryo
implantation and development. These
include genes encoding lysosomal enzymes
Toxicogenomics | Moggs et al.
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Figure 8. Evidence for a transcriptional regulatory network during the uterotrophic response.
(A) Organization of mouse SPRR genomic locus that is coordinately regulated by the transcription factors
AP-1 and Ets. (B)E 2-induced expression (mean + SD) of genes encoding AP-1 and Ets transcription fac-
tors temporally precedes the coordinate regulation of the tandem array of SPRR genes. (C) Feed-forward
model for an ER-dependent transcriptional cascade in the uterus. Transcriptional regulators are repre-
sented by blue circles. Gene promoters are represented by white rectangles. See Appendix for gene
nomenclature and Affymetrix probe sets.
2A
2B
2C
2D
2E 2H
2F
1B 1A
2K
3
2J
2I
2G
4
Mouse SPRR locus
(~220 kb; chromosome 3)
ETS2
ATF3 SPRR2C
SPRR2G
SPRR2I
JUN
SPRR2J JUNB
FOS SPRR2A
FOSB SPRR2F
SPRR2E ATF5
ATF4 SPRR1A
3
2
1
8
6
4
2
4
3
2
1
18
14
10
6
2
30
25
20
15
10
5
3
2
1
5
4
3
2
1
4
3
2
1
40
30
20
10
400
300
200
100
12
10
8
6
4
2
9
7
5
3
1
90
70
50
30
10
120
80
40
16
12
8
4
12
8
4
ER FOS, JUN, ATF, ETS AP-1 Ets
SPRR locus
1 2 4 8 24 48 72
Time (hr)
1 2 4 8 24 48 72
Time (hr)
M
e
a
n
 
(
+
 
S
D
)
 
c
h
a
n
g
e
 
i
n
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
r
a
t
i
o
 
E
2
:
A
O
)
B
A
C(LYZP, LYZM, CTSH CTSL, CTSS,
LGMN), genes involved in detoxification
and clearance of xenobiotics (GSTO1,
GSTT2, UGT1A1), and genes involved in
immune and inflammatory responses
(CD14, MX1, PIGR). The up-regulation of
genes encoding chemoattractant cytokines
(Figure 7C) for infiltrating eosinophils
(EOTAXIN) and monocytes (MCP1/3) is
consistent with previous observations of
immune cell infiltration into the uterus
(Gouon-Evans and Pollard 2001, and ref-
erences therein). Another E2-regulated
defense response may be provided by the
induction of LTF (Liu and Teng 1992), an
iron-binding protein with bacteriostatic
activity (Singh et al. 2002). Our data reveal
the induction of two additional iron
metabolism genes at this time (CP, LCN2;
Figure 7E; Kaplan 2002), suggesting a role
for iron homeostasis in the uterotrophic
response to E2.
Several components of the complement
system are also induced 48–72 hr after
exposure to E2. These include C1QA,
C1QB, C1QC, C2, C3, C4, CFH, and CFI
(Figure 7D). Although many complement
components have been identiﬁed in female
reproductive epithelium, only C3 has pre-
viously been established as an E2-responsive
gene (Sundstrom et al. 1989). In addition
to participating in immune and inﬂamma-
tory responses and host resistance, there is
increasing evidence that complement func-
tions in tissue remodeling and organ regen-
eration (Mastellos and Lambris 2002).
Intriguingly, complement also influences
mammalian reproduction and particularly
the integrity of maternofetal interfaces dur-
ing pregnancy (Caucheteux et al. 2003;
Mastellos and Lambris 2002). Therefore, it
is possible that the complement system
may play a noninflammatory role in the
uterotrophic response.
Evidence for a Transcriptional
Cascade in the Uterus
It is striking that many different induction
profiles can be seen in the genes regulated
by E2: some genes are induced within 1 hr
of exposure, whereas others are not induced
until 48 hr (Figure 3B). The induction of a
large number of sequence-speciﬁc transcrip-
tion factors during the first phase of the
response suggests that a transcriptional cas-
cade may operate in the uterus, with the
products of genes induced at the beginning
of the program regulating the transcription
of those toward the end. The regulation of
the SPRR genes provides evidence for the
existence of such a cascade (Figure 8). The
mouse SPRR genes are located in a tandem
array at the same chromosomal locus, and
their transcription is regulated by the AP-1
and Ets transcription factors (Patel et al.
2003; Figure 8A). Eight members of the
SPRR gene family are induced between 4
and 72 hr, with maximal induction occur-
ring between 24 and 48 hr (Figure 8B).
Intriguingly, the mRNAs encoding Ets2
and components of AP-1 (c-Jun, JunB,
c-Fos, FosB, and Atf3, Atf4, Atf5) are maxi-
mally induced during the ﬁrst phase of the
uterotrophic response, between 1 and 4 hr
(Figure 8B). We speculate, therefore, that a
transcriptional cascade operates, in which
ER-α or ER-β induces the expression of
Ets2 and AP-1 components, which in turn
regulate the transcription of the SPRR
genes (Figure 8C). Alternatively, it is possi-
ble that ER-α or ER-β cooperates with
Ets2 and AP-1 to regulate the expression of
the SPRR genes. In this way, transcription
of the SPRR genes would not begin until
sufﬁcient levels of Ets2 and AP-1 were pre-
sent. Consistent with this model, feed-for-
ward loops (in which a transcriptional
regulator controls a second transcription
factor that then functions in concert with
the initial regulator on a common down-
stream target gene) are emerging as
common mechanisms in eukaryotes for
transcriptional networks (Lee et al. 2002).
It is likely that analysis of the regulatory
regions of other E2-responsive genes during
the uterotrophic response will suggest the
existence of additional transcriptional
networks.
Discussion
Our data describe at an unprecedented
level of detail the molecular events that
initiate and drive uterine physiologic
changes upon exposure to the sex steroid
hormone E2 in the immature mouse
uterus. Gene expression profiling reveals
that E2 induces a multistage and tightly
coordinated transcriptional program that
regulates successive and functionally inter-
linked cellular processes during the
uterotrophic response (Figure 9). The tem-
poral patterns of gene expression we have
identified for E2 are consistent with, and
extend, those reported recently for the
uterotrophic response of immature,
ovariectomized mice after exposure to
17α-ethynylestradiol (Fertuck et al. 2003),
in which concordant temporal responses
were seen for genes involved in several
functional categories in Figure 9. These
include RNA and protein metabolism, cell
cycle regulation, immune responses, and
complement components. Furthermore,
many of the genes regulated by exogenous
E2 in our study are also differentially regu-
lated in response to endogenous hormones
(Tan et al. 2003).
Comparison of gene expression changes
with alterations in uterine weight and his-
tologic alterations, and analysis of gene
expression data according to gene function
allowed us to implicate specific groups of
genes in driving water imbibition in the
stromal endothelium, synchronous cell
proliferation, and cytoarchitectural changes
associated with luminal epithelial cell dif-
ferentiation. These data thus provide a
detailed mechanistic view of the relation-
ships between the uterotrophic response
and the underlying transcriptional
program. Furthermore, this work demon-
strates that comparison of temporal
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Figure 9. Summary of the transcriptional program associated with E2-induced uterine growth showing the
successive regulation of genes with distinct molecular functions.changes in gene expression and conven-
tional toxicology parameters (uterine
weight and histologic changes) can provide
an understanding of the relationships
between gene expression patterns and
phenotypic change.
E2 can regulate transcription through a
combination of at least two distinct signal-
ing pathways: a) via activation of the
nuclear transcription factors ER-α and
ER-β (Hall et al. 2001; McKenna and
O’Malley 2002; Moggs and Orphanides
2001; Tremblay and Giguere 2002) and
b) via extranuclear or “nongenomic” signal-
ing events (Falkenstein et al. 2000;
Hammes 2003; Moggs et al. 2003). The
transcriptional responses to E2 that we have
deﬁned here are likely to involve a combi-
nation of direct gene regulation by nuclear
ERs and indirect gene regulation via
extranuclear signaling pathways. Although
the uterus of the immature mouse expresses
both ER subtypes (α and β) at comparable
levels (Weihua et al. 2000), recent tran-
script profiling studies using ovari-
ectomized ER-knockout mice revealed a
predominant role for ER-α in the regula-
tion of estrogen-responsive genes in the
uterus (Hewitt et al. 2003; Watanabe et al.
2003) consistent with the observation that
only a partial uterotrophic response occurs
in ER-α knockout mice (Lubahn et al.
1993). Therefore, it is likely that most
E2-responsive genes we have identified are
regulated by ER-α. However, identiﬁcation
of the direct gene targets for each ER sub-
type will ultimately require the develop-
ment of methods for measuring the
occupancy of receptor subtypes at promot-
ers in vivo. Nevertheless, our temporal
analysis of E2-responsive genes provides
novel insights into the transcriptional cas-
cades that are initiated through E2-respon-
sive transcription factors.
The molecular events described here for
the reference natural estrogen E2 provide
the basis for understanding how other
estrogenic chemicals, including synthetic
estrogens and phytoestrogens, induce their
effects (Moggs et al. 2004). Increasing
attention is being paid to the use of gene
expression changes in the uterus for the
identification of surrogate markers for
short-term rodent estrogenicity assays
(Naciff et al. 2002, 2003; Owens and
Ashby 2002; Watanabe et al. 2002), and
our data reveal a large number of novel
candidate marker genes. The insights pro-
vided by these data, into how an ER ligand
coordinates transcriptional regulatory net-
works that result in proliferation and dif-
ferentiation in a complex organ, provide a
paradigm for understanding the modes of
action of other nuclear receptors.
REFERENCES
Affymetrix, Inc. 2002. GeneChip Expression Analysis:
Technical Manual. Available: http//www.
affymetrix.com/support/technical/manual/
expression.manual.affx.
Amin RP, Vickers AE, Sistare F, Thompson KL,
Roman RJ, Lawton M, et al. 2004. Identiﬁcation of
putative gene based markers of renal toxicity.
Environ Health Perspect 112(4):465–479.
Beissbarth T, Speed TP. 2004. GOstat: find statisti-
cally overrepresented gene ontologies within a
group of genes. Bioinformatics 20:1464–1465.
Caucheteux SM, Kannellopoulos-Langevin C, Ojcius
DM. 2003. At the innate frontiers between mother
and fetus: linking abortion with complement acti-
vation. Immunity 18:169–172.
Churchill GA. 2004. Using ANOVA to analyze microar-
ray data. Biotechniques 37:173–175.
Clark JH, Mani SK. 1994. Actions of ovarian steroid
hormones. In: The Physiology of Reproduction
(Knobil E, Neill J, eds). Vol 1, 2nd ed. New
York:Raven Press, 1011–1059.
Cui X, Churchill GA. 2003. Statistical tests for differen-
tial expression in cDNA microarray experiments.
Genome Biol 4:210.1–210.10.
Cunningham ML, Irwin R, Boorman G. 2003. Tox/path
team takes on differential gene expression.
Environ Health Perspect 111:A814–A815.
Falkenstein E, Tillmann H-C, Christ M, Feuring M,
Wehling M. 2000. Multiple actions of steroid hor-
mones—a focus on rapid, non-genomic effects.
Pharmacol Rev 52:513–555.
Fertuck KC, Eckel JE, Gennings C, Zacharewski TR.
2003. Identification of temporal patterns of gene
expression in the uteri of immature, ovariec-
tomized mice following exposure to ethynylestra-
diol. Physiol Genomics 15:127–141.
Gant TW, Baus PR, Clothier B, Riley J, Davies R,
Judah DJ, et al. 2003. Gene expression profiles
associated with inflammation, fibrosis, and
cholestasis in mouse liver after griseofulvin.
Environ Health Perspect 111:37–43.
Gouon-Evans V, Pollard JW. 2001. Eotaxin is required for
eosinophil homing into the stroma of the pubertal
and cycling uterus. Endocrinology 142:4515–4521.
Hall JM, Couse JF, Korach KS. 2001. The multifaceted
mechanisms of estradiol and estrogen receptor
signaling. J Biol Chem 276:36869–36872.
Hamadeh HK, Jayadev S, Gaillard ET, Huang Q, Stoll R,
Blanchard K, et al. 2004. Integration of clinical and
gene expression endpoints to explore furan-medi-
ated hepatotoxicity. Mutat Res 549:169–183.
Hammes SR. 2003. The further redefining of steroid-
mediated signaling. Proc Natl Acad Sci USA 100:
2168–2170.
Heinloth AN, Irwin RD, Boorman GA, Nettesheim P,
Fannin RD, Sieber SO, et al. 2004. Gene expres-
sion profiling of rat livers reveals indicators of
potential adverse effects. Toxicol Sci 80:193–202.
Hewitt SC, Deroo BJ, Hansen K, Collins J, Grissom S,
Afshari CA, et al. 2003. Estrogen receptor-depen-
dent genomic responses in the uterus mirror the
biphasic physiological response to estrogen. Mol
Endocrinol 17:2070–2083.
Kaplan J. 2002. Mechanisms of cellular iron acquisi-
tion: another iron in the ﬁre. Cell 111:603–606.
Kaye AM, Sheratzky D, Lindner HR. 1971. Kinetics of
DNA synthesis in immature rat uterus: age
dependence and estradiol stimulation. Biochim
Biophys Acta 261:475–486.
Koepp DM, Harper JW, Elledge SJ. 1999. How the
cyclin became a cyclin: regulated proteolysis in
the cell cycle. Cell 97:431–434.
Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z,
Gerber GK, et al. 2002. Transcriptional regulatory
networks in Saccharomyces cerevisiae. Science.
298:799–804.
Liu G, Loraine AE, Shigeta R, Cline M, Cheng J,
Valmeekam V, et al. 2003. NetAffx: Affymetrix
probesets and annotations. Nucleic Acids Res
31:82–86.
Liu Y, Teng CT. 1992. Estrogen response module of
the mouse lactoferrin gene contains overlapping
chicken ovalbumin upstream promoter transcrip-
tion factor and estrogen receptor-binding ele-
ments. Mol Endocrinol 6:355–364.
Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR,
Afshari CA. 2002. Regulation of DNA replication
fork genes by 17beta-estradiol. Mol Endocrinol
16:1215–1229.
Lubahn DB, Moyer JS, Golding TS, Couse JF,
Korach KS, Smithies O. 1993. Alteration of repro-
ductive function but not prenatal sexual develop-
ment after insertional disruption of the mouse
estrogen receptor gene. Proc Natl Acad Sci USA
90:11162–11166.
Mastellos D, Lambris JD. 2002. Complement: more
than a ‘guard’ against invading pathogens?
Trends Immunol 23:485–491.
McKenna NJ, O’Malley BW. 2002. Combinatorial con-
trol of gene expression by nuclear receptors and
coregulators. Cell 108:465–474.
Metivier R, Penot G, Hubner MR, Reid G, Brand H,
Kos M, et al. 2003. Estrogen receptor-alpha
directs ordered, cyclical, and combinatorial
recruitment of cofactors on a natural target pro-
moter. Cell 115:751–763.
Moggs JG, Ashby J, Tinwell H, Lim F-L, Moore D,
Kimber I, et al. 2004. The need to decide if all
estrogens are intrinsically similar. Environ Health
Perspect 112:1137–1142.
Moggs JG, Deavall DG, Orphanides G. 2003. Sex
steroids, ANGELS and osteoporosis. Bioessays
25:195–199.
Moggs JG, Orphanides G. 2001. Estrogen receptors:
orchestrators of pleiotropic cellular responses.
EMBO Rep 2:775–781.
Naciff JM, Jump ML, Torontali SM, Carr GJ,
Tiesman JP, Overmann GJ, et al. 2002. Gene
expression profile induced by 17alpha-ethynyl
estradiol, bisphenol A, and genistein in the develop-
ing female reproductive system of the rat. Toxicol
Sci 68:184–199.
Naciff JM, Overmann GJ, Torontali SM, Carr GJ,
Tiesman JP, Richardson BD, et al. 2003. Gene
expression profile induced by 17 alpha-ethynyl
estradiol in the prepubertal female reproduc-
tive system of the rat. Toxicol Sci 72:314–330.
Norbury C, Nurse P. 1992. Animal cell cycles and
their control. Annu Rev Biochem 61:441–470.
Odum J, Lefevre PA, Tittensor S, Paton D, Routledge
EJ, Beresford NA, et al. 1997. The rodent
uterotrophic assay: critical protocol features,
studies with nonyl phenols, and comparison with
a yeast estrogenicity assay. Regul Toxicol
Pharmacol 26:176–188.
Ohtani K. 1999. Implication of transcription factor E2F
in regulation of DNA replication. Front Biosci
4:D793–D804.
Olashaw N, Pledger WJ. 2002. Paradigms of growth
control: relation to Cdk activation. Sci STKE
134:RE7.
Orphanides G, Reinberg D. 2002. A unified theory of
gene expression. Cell 108:439–451.
Owens JW, Ashby J. 2002. Critical review and evalu-
ation of the uterotrophic bioassay for the identiﬁ-
cation of possible estrogen agonists and
Toxicogenomics | Moggs et al.
1600 VOLUME 112 | NUMBER 16 | November 2004 • Environmental Health Perspectivesantagonists: in support of the validation of the
OECD uterotrophic protocols for the laboratory
rodent. Organisation for Economic Co-operation
and Development. Crit Rev Toxicol 32:445–520.
Paria BC, Reese J, Das SK, Dey SK. 2003. Deciphering
the cross-talk of implantation: advances and
challenges. Science 296:2185–2188.
Patel S, Kartasova T, Segre JA. 2003. Mouse SPRR
locus: a tandem array of coordinately regulated
genes. Mamm Genome 14:140–148.
Paules R. 2003. Phenotypic anchoring: linking
cause and effect. Environ Health Perspect
111:A338–A339.
Perillo B, Sasso A, Abbondanza C, Palumbo G. 2000.
17beta-Estradiol inhibits apoptosis in MCF-7
cells, inducing bcl-2 expression via two estro-
gen-responsive elements present in the coding
sequence. Mol Cell Biol 20:2890–2901.
Quackenbush J. 2002. Microarray data normalization
and transformation. Nat Genet 32(suppl):496–501.
Quarmby VE, Korach KS. 1984. Differential regulation
of protein synthesis by estradiol in uterine
component tissues. Endocrinology 114:694–702.
SAS Institute Inc. 1999. SAS/STAT User’s Guide,
Version 8. Cary, NC:SAS Institute Inc.
Schmidt CW. 2003. Toxicogenomics. Environ Health
Perspect 111:A20–A25.
Shaulian E, Karin M. 2001. AP-1 in cell proliferation
and survival. Oncogene 20:2390–2400.
Singh PK, Parsek MR, Greenberg EP, Welsh MJ. 2002.
A component of innate immunity prevents bacter-
ial bioﬁlm development. Nature 417:552–555.
Soulez M, Parker MG. 2001. Identification of novel
oestrogen receptor target genes in human ZR75-
1 breast cancer cells by expression profiling. J
Mol Endocrinol 27:259–274.
Sundstrom SA, Komm BS, Ponce-de-Leon H, Yi Z,
Teuscher C, Lyttle CR. 1989. Estrogen regulation
of tissue-specific expression of complement C3.
J Biol Chem 264:16941–16947.
Tan YF, Li FX, Piao YS, Sun XY, Wang YL. 2003. Global
gene profiling analysis of mouse uterus during
the oestrous cycle. Reproduction 126:171–182.
Thompson EB. 1994. Apoptosis and steroid hormones.
Mol Endocrinol 8:665–671.
Tremblay GB, Giguere V. 2002. Coregulators of estro-
gen receptor action. Crit Rev Eukaryot Gene Expr
12:1–22.
Watanabe H, Suzuki A, Kobayashi M, Takahashi E,
Itamoto M, Lubahn DB, et al. 2003. Analysis of
temporal changes in the expression of
estrogen-regulated genes in the uterus. J Mol
Endocrinol 30:347–358.
Watanabe H, Suzuki A, Mizutani T, Khono S, Lubahn
DB, Handa H, et al. 2002. Genome-wide analysis
of changes in early gene expression induced by
oestrogen. Genes Cells 7:497–507.
Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV,
Warner M, et al. 2000. Estrogen receptor (ER)
beta, a modulator of ERalpha in the uterus. Proc
Natl Acad Sci USA 97:5936–5941.
Weisz A, Bresciani F. 1988. Estrogen induces expres-
sion of c-fos and c-myc protooncogenes in rat
uterus. Mol Endocrinol 2:816–824.
Weitlauf HM. 1994. Biology of implantation. In: The
Physiology of Reproduction (Knobil E, Neill J, eds).
Vol 1, 2nd ed. New York:Raven Press, 391–440.
Zhu T, Budworth P, Han B, Brown D, Chang HS, Zou G,
et al. 2001. Toward elucidating the global gene
expression patterns of developing Arabidopsis:
parallel analysis of 8300 genes by high-density
oligonucleotide probe array. Plant Physiol
Biochem 39:221–242. 
Toxicogenomics | Uterotrophic transcriptional program
Environmental Health Perspectives • VOLUME 112 | NUMBER 16 | November 2004 1601
Appendix. Gene nomenclature and Affymetrix probe sets for Figures 4–8.a
Gene symbol Affymetrix Probe Set Gene description
Figure 4B—Signaling components
IL17R 99992_at interleukin 17 receptor
RAP1 160822_at Rap1, GTPase-activating protein 1
DEXRAS1 99032_at RAS, dexamethasone-induced 1
MKP1 104598_at dual speciﬁcity phosphatase 1
WNT4 103238_at wingless-related MMTV integration site 4
IGFBP10 92777_at cysteine rich protein 61
PIP92 99109_at immediate early response 2
PIM3 96841_at similar to serine/threonine-protein kinase pim-3
ARHU 96747_at ras homolog gene family, member U
CISH3 162206_f_at cytokine inducible SH2-containing protein 3
NAB2 100962_at Ngﬁ-A binding protein 2
SOCS3 92232_at cytokine inducible SH2-containing protein 3
EPLG2 98407_at ligand for receptor tyrosine kinase ELK
IL17R 99991_at interleukin 17 receptor
CDKN1A 98067_at cyclin-dependent kinase inhibitor 1A (P21)
CDKN1A 94881_at cyclin-dependent kinase inhibitor 1A (P21)
WSB1 98946_at WD-40-repeat-containing protein with a SOCS box 
VEGF 103520_at vascular endothelial growth factor A
GADD45 102292_at growth arrest and DNA-damage-inducible 45
SYT 99610_at synovial sarcoma translocation, chromosome 18
SOCS1 92832_at cytokine inducible SH2-containing protein 1
GADD45g 101979_at growth arrest and DNA-damage-inducible 45 gamma
GLY96 94384_at immediate early response 3
MAPKAP2 160353_i_at MAP kinase-activated protein kinase 2
KLK22 101289_f_at epidermal growth factor binding protein type 1
TROB 99532_at tob family
RGS3 160747_at regulator of G-protein signaling 3
GNA13 100514_at guanine nucleotide binding protein, alpha 13
RAB11A 96238_at RAB11a, member RAS oncogene family
PLGF 92909_at placental growth factor
BDKRB1 101748_at bradykinin B1 subtype receptor
CF3 97689_at coagulation factor III
PDK4 102049_at pyruvate dehydrogenase kinase, isoenzyme 4
HERPUD1 95057_at homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1
MYD116 160463_at myeloid differentiation primary response gene 116
NORE1 102028_at Ras association (RalGDS/AF-6) domain family 5
NET1A 94223_at neuroepithelial cell transforming gene 1
GEM 92534_at GTP binding protein (gene overexpressed in 
skeletal muscle)
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Appendix. Continued
Gene symbol Affymetrix Probe Set Gene description
SNRK 97429_at SNF related kinase
ALASH 93500_at aminolevulinic acid synthase 1
NTTP1 161171_at dual speciﬁcity phosphatase 8
MAPKAP2 95721_at MAP kinase-activated protein kinase 2
MEK1 92585_at mitogen activated protein kinase kinase 1
RGSr 94378_at regulator of G-protein signaling 16
RASSF1 102379_at Ras association (RalGDS/AF-6) domain family 1
NGEF 93178_at neuronal guanine nucleotide exchange factor
C-KIT 99956_at kit oncogene
NOTCH1 97497_at Notch gene homolog 1
BTG3 96146_at B-cell translocation gene 3
PC4 160092_at interferon-related developmental regulator 1
SGK 97890_at serum/glucocorticoid regulated kinase
ADM 102798_at adrenomedullin
ANGPT2 92210_at angiopoietin 2
UBQLN1 95601_at ubiquilin 1
THBS1 160469_at thrombospondin
ROCK2 98504_at rho-associated coiled-coil forming kinase 2
SNK 92310_at serum-inducible kinase
MAP2K3 93315_at mitogen activated protein kinase kinase 3
ENG 100134_at endoglin
PTDSR 95486_at phosphatidylserine receptor
SWIP2 160296_at WD-40-repeat-containing protein with a SOCS box 
AKT 100970_at thymoma viral proto-oncogene 1
RHOC 96056_at ras homolog gene family, member C
TGFB2 93300_at transforming growth factor, beta 2
EPCR 98018_at protein C receptor, endothelial
KLK6 100061_f_at kallikrein 6
GALN 100407_at galanin
NEDD4B 103907_at neural precursor cell expressed, developmentally down-
regulated gene 4-like
KLK22 95775_f_at kallikrein 22
KLK9 94716_f_at kallikrein 9
MCP1 102736_at platelet-derived growth factor-inducible protein JE
TIE1 99936_at tyrosine kinase receptor 1
RAMP1 104680_at receptor (calcitonin) activity modifying protein 1
PGF 97769_at prostaglandin F receptor
PDGFαRA 95079_at platelet derived growth factor receptor, alpha polypeptide
OB-RGRP 93600_at leptin receptor
ERK1 101834_at mitogen activated protein kinase 3
GRB7 103095_at growth factor receptor bound protein 7
ADCY6 102321_at adenylate cyclase 6
TIE1 161184_f_at tyrosine kinase receptor 1
GNAI1 104412_at guanine nucleotide binding protein, alpha inhibiting 1
ADCY7 103392_at adenylate cyclase 7
TIE2 102720_at endothelial-speciﬁc receptor tyrosine kinase
GPCR26 100435_at endothelial differentiation, lysophosphatidic acid 
G-protein-coupled receptor, 2
Figure 4C—Transcription factors
GIF 99603_g_at TGFB inducible early growth response
GIF 99602_at TGFB inducible early growth response
ETS2 94246_at E26 avian leukemia oncogene 2, 3’ domain
ID1 100050_at inhibitor of DNA binding 1
SMAD7 92216_at MAD homolog 7
C-JUN 100130_at Jun oncogene
BRF2 160273_at zinc ﬁnger protein 36, C3H type-like 2
IRF8 98002_at interferon concensus sequence binding protein
AGP/EBP 92925_at CCAAT/enhancer binding protein (C/EBP), beta
C-FOS 160901_at c-fos oncogene
KROX24 98579_at zinc ﬁnger protein Krox-24
FOSB 103990_at FBJ osteosarcoma oncogene B
NR4A1 102371_at N10 nuclear hormonal binding receptor
SOX18 161025_f_at SRY-box containing gene 18
SOX18 104408_s_at SRY-box containing gene 18
KROX20 102661_at Early growth response 2
ESG 104623_at transducin-like enhancer of split 3, homolog of 
Drosophila E(spl)
FOG 97974_at zinc ﬁnger protein, multitype 1
NCOR2 95129_at nuclear receptor co-repressor 2
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Gene symbol Affymetrix Probe Set Gene description
SOX11 101631_at SRY-box containing gene 11
C/EBP 94466_f_at CCAAT/enhancer binding protein alpha (C/EBP), 
related sequence 1
PRX2 103327_at paired related homeobox 2
ATF4 100599_at activating transcription factor 4
STAT5B 100422_i_at signal transducer and activation of transcription 5A
HEY1 95671_at hairy/enhancer-of-split related with YRPW motif 1
ATF5 103006_at activating transcription factor 5
C/EBP 98447_at CCAAT/enhancer binding protein
RIP140 103288_at nuclear receptor interacting protein 1
CRTR1 103761_at Tcfcp2-related transcriptional repressor 1
MEF2A 93852_at myocyte enhancer factor 2A
TIS11 92830_s_at zinc ﬁnger protein 36
STAT5B 100423_f_at signal transducer and activation of transcription 5A
ATF3 104155_f_at activating transcription factor 3
CART1 100005_at TNF receptor associated factor 4
JUNB 102362_i_at transcription factor junB
Figure 5A—RNA synthesis
SFPQ 99621_s_at splicing factor proline/glutamine rich (polypyrimidine
tract binding protein associated)
U2AF1 97486_at U2 small nuclear ribonucleoprotein auxiliary factor 
(U2AF), 35 kDa
RBMXP1 160192_at RNA binding motif protein, X chromosome retrogene
DDX21 94361_at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21
(RNA helicase II/Gu)
DDX3 101542_f_at DEAD (aspartate-glutamate-alanine-aspartate)
box polypeptide 3
NSAP1 94985_at NS1-associated protein 1
MKI67 bp 93342_at Mki67 (FHA domain) interacting nucleolar phosphoprotein
ELAVL1 94001_at ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1
(Hu antigen R)
PSP1 103393_at paraspeckle protein 1
SRP20 101003_at splicing factor, arginine/serine-rich 3 (SRp20)
JKTBP 96084_at heterogeneous nuclear ribonucleoprotein D-like
RPA2 92225_f_at RNA polymerase 1–2 (128 kDa subunit)
RALY 98511_at hnRNP-associated with lethal yellow
SFRS10 95791_s_at splicing factor, arginine/serine-rich 10
FBL 160503_at ﬁbrillarin
SNRPA1 101506_at small nuclear ribonucleoprotein polypeptide A’
TASR 98048_at neural-salient serine/arginine-rich
RPB10 93551_at RNA polymerase II subunit 10
AUF1 94303_at heterogeneous nuclear ribonucleoprotein D
HRMT1L2 96696_at heterogeneous nuclear ribonucleoproteins
methyltransferase-like 2
CGI-110 95714_at pre-mRNA branch site protein p14
SMN 103620_s_at survival motor neuron
RPB8 97254_at RNA binding motif protein
RNPS1 93518_at ribonucleic acid binding protein S1
NCL 160521_at nucleolin
RPA1 93620_at RNA polymerase 1–4 (194 kDa subunit)
HNRPA2B1 93118_at heterogeneous nuclear ribonucleoprotein A2/B1
SNRPD1 100577_at small nuclear ribonucleoprotein D1
H/ALAsnRNP 97824_at nucleolar protein family A, member 2
TAF10 103910_at TAFII30
DDX24 99096_at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 13
(RNA helicase A)
Figure 5B
MAD4 99024_at Max dimerization protein 4
EZH1 100486_at enhancer of zeste homolog 1 (Drosophila)
HDA1 104376_at histone deacetylase 5
AUH 96650_at AU RNA binding protein/enoyl-coenzyme A hydratase
TGIF 101502_at TG interacting factor
Figure 5C—Nuclear import/export
POM121 96174_at nuclear pore membrane protein 121
NXF1 101079_at nuclear RNA export factor 1 homolog (S. cerevisiae)
IMPORTINa3 96010_at karyopherin (importin) alpha 3
RAE1 160466_at RNA export 1 homolog (S. pombe)
IMPORTINa2 92790_at karyopherin (importin) alpha 2
G3BP2 94913_at Ras-GTPase-activating protein (GAP120)
SH3-domain binding protein 2
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Gene symbol Affymetrix Probe Set Gene description
Figure 5D—Protein translation
eIF3S7 99101_at eukaryotic translation initiation factor 3, subunit 7 
(zeta, 66/67kDa)
eIF2B 160365_at eukaryotic translation initiation factor 2, subunit 2 
(beta, 38kDa)
eIF3S4 96883_at eukaryotic translation initiation factor 3, subunit 4 
(delta, 44kDa)
EBNA1-bp2 96297_at EBNA1 binding protein 2
GLNRS 96628_at glutamyl-prolyl-tRNA synthetase
NAT1 100535_at eukaryotic translation initiation factor 4, gamma 2
eIF3S9 93973_at eukaryotic translation initiation factor 3, subunit 9
RPS18b 95159_at ribosomal protein S18b
VALRS 97894_at valyl-tRNA synthetase 2
RPL12 160431_at mitochondrial ribosomal protein L12
eIF1A 93058_at eukaryotic translation initiation factor 1A
eRF1 160451_at translation releasing factor eRF1
eIF1A 103708_at eukaryotic translation initiation factor 1A
eIF6 94826_at integrin beta 4 binding protein
eRF1 98608_at translation releasing factor eRF1
RPL20 94875_at mitochondrial ribosomal protein L20
PHERS 94494_at phenylalanine-tRNA synthetase-like
ASNS 95133_at asparagine synthetase
eIF3S10 94250_at eukaryotic translation initiation factor 3
NOP56 95109_at nucleolar protein 5A
eIF2AS1 94253_at eukaryotic translation initiation factor 2A
RRS1 96778_at regulator for ribosome resistance homolog 
(S. cerevisiae)
eRF1 96755_at translation releasing factor eRF1
eRF1 96754_s_at translation releasing factor eRF1
SUI1 92855_at suppressor of initiator codon mutations,
related sequence 1 (S. cerevisiae)
RPL11 98876_at mitochondrial ribosomal protein L11
RPL52 97443_at mitochondrial ribosomal protein L52
Figure 5E—Protein folding
CCT3 98153_at chaperonin subunit 3 (gamma)
FKBP4 92808_f_at FK506 binding protein 4 (59 kDa)
CCT7 160562_at chaperonin subunit 7 (eta)
PPID 97445_at peptidylprolyl isomerase D (cyclophilin D)
CCT10 92829_at heat shock 10 kDa protein 1 (chaperonin 10)
CCT8 160102_at chaperonin subunit 8 (theta)
CCT6A 162279_f_at chaperonin subunit 6a (zeta)
CCT3 161238_f_at chaperonin subunit 3 (gamma)
Figure 5F—Protein degradation
PAD1 97274_at 26S proteasome-associated pad1 homolog
PSMB5 101558_s_at proteasome (prosome, macropain) subunit, beta type 5
PSMD4 94302_at proteasome (prosome, macropain) 26S subunit,
non-ATPase, 4
PSMB3 94025_at proteasome (prosome, macropain) 
subunit, beta type 3
SUG1 160534_at protease (prosome, macropain) 26S subunit, ATPase 5
PSMB6 101992_at proteasome (prosome, macropain) subunit, beta type 6
PSMB2 94219_at proteasome (prosome, macropain) subunit, beta type 2
Figure 6B—DNA replication and cell division
SAKB 98996_at serine/threonine kinase 18
RRM2 102001_at ribonucleotide reductase M2
CAF1 p60 100890_at chromatin assembly factor, p60 subunit
ORC6 95712_at origin recognition complex, subunit 6-like (S. cerevisiae)
PCNA 101065_at proliferating cell nuclear antigen
MCM2 93112_at mini chromosome maintenance deﬁcient 2
CDC6 103821_at cell division cycle 6 homolog (S. cerevisiae)
MCM4 93041_at mini chromosome maintenance deﬁcient 4 homolog
MCM3 160496_s_at mini chromosome maintenance deﬁcient (S. cerevisiae)
MCM3 100062_at mini chromosome maintenance deﬁcient (S. cerevisiae)
TOPB1 103071_at topoisomerase (DNA) II binding protein
CHK1 103064_at checkpoint kinase 1 homolog (S. pombe)
MCM5 100156_at mini chromosome maintenance deﬁcient 5
CKS1 97468_at CDC28 protein kinase 1
ORC1 92458_at origin recognition complex, subunit 1-like (S. cerevisiae)
RRM1 100612_at ribonucleotide reductase M1
FEN1 97327_at ﬂap structure speciﬁc endonuclease 1
Continued, next pageToxicogenomics | Uterotrophic transcriptional program
Environmental Health Perspectives • VOLUME 112 | NUMBER 16 | November 2004 1605
Appendix. Continued
Gene symbol Affymetrix Probe Set Gene description
GEMININ 160069_at geminin
E2F1 102963_at E2F transcription factor 1
PLK1 93099_f_at polo-like kinase homolog (Drosophila)
CCNB1 160159_at cyclin B1, related sequence 1
Figure 6C—Cell-cycle regulators
CCND1 94232_at cyclin D1
CDC34 94048_at cell division cycle 34 homolog
KIP2 95471_at cyclin-dependent kinase inhibitor 1C (P57)
CCNG2 98478_at cyclin G2
KIP1 161010_r_at cyclin-dependent kinase inhibitor (p27)
CCNI 94819_f_at cyclin I
Figure 6D—Apoptosis
CASP2 99049_at caspase 2
NIX 96255_at BCL2/adenovirus E1B 19 kDa-interacting protein 3-like
APR3 160271_at apoptosis related protein APR3
TNFSF12 93917_at tumor necrosis factor (ligand) superfamily, member 12
PDCD4 103029_at programmed cell death 4
MIAP2 102734_at baculoviral IAP repeat-containing 3
MTD 98031_at Bcl-2-related ovarian killer protein
SDNSF 97451_at neural stem cell derived neuronal survival protein
DAD1 96008_at defender against Apoptotic Death 1
AAC11 101035_at apoptosis inhibitor 5
BAG3 96167_at Bcl2-associated athanogene 3
BAG2 161129_r_at similar to BAG-family molecular chaperone regulator-2
Figure 7A—Cytoarchitecture
MDEG2 99910_at amiloride-sensitive cation channel 1, neuronal (degenerin)
MAT8 103059_at FXYD domain-containing ion transport regulator 3
CLCA3 162287_r_at chloride channel calcium activated 3
CD133 93389_at prominin
CD133 93390_g_at prominin
PIGF 104725_at ras-like protein
DSG2 104480_at desmoglein 2
MAN2B1 99562_at mannosidase 2, alpha B1
CLDN4 101410_at claudin 4
CLDN7 99561_f_at claudin 7
SPRR2E 100723_f_at small proline-rich protein 2E
SPRR2J 101755_f_at small proline-rich protein 2J
SPRR2A 101025_f_at small proline-rich protein 2A
TROP2 103648_at tumor-associated calcium signal transducer 2
SPRR2I 95794_f_at small proline-rich protein 2I
SPRR2C 101761_f_at small proline-rich protein 2C
SPRR2A 101024_i_at small proline-rich protein 2A
LRG 97420_at leucine-rich alpha-2-glycoprotein
TROP2 160651_at tumor-associated calcium signal transducer 2
SPRR2G 101754_f_at small proline-rich protein 2G
SPRR2F 94120_s_at small proline-rich protein 2F
BGP1 102805_at CEA-related cell adhesion molecule 1
BGP1 102804_at CEA-related cell adhesion molecule 1
BGP1 102806_g_at CEA-related cell adhesion molecule 1
BGP2 101908_s_at CEA-related cell adhesion molecule 2
CX26 98423_at connexin 26
MUC1 102918_at mucin 1, transmembrane
SPP1 97519_at secreted phosphoprotein 1
CLU 161294_f_at clusterin
CLU 95286_at clusterin
CFTR 94757_at cystic ﬁbrosis transmembrane conductance 
regulator homolog 
KRT19 92550_at keratin complex 1, acidic, gene 19
KRT19 102121_f_at keratin complex 1, acidic, gene 19 
SPRR1A 160909_at small proline-rich protein 1A
GALNT3 162313_f_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 3
Figure 7B—Defense responses
PLGR 99926_at polyimmunoglobulin receptor
CTSL 101963_at cathepsin L
LAMP1 100136_at lysosomal membrane glycoprotein 2
CTSS 98543_at cathepsin S
GSTO1 97819_at glutathione S-transferase omega 1
GSTT2 104603_at glutathione S-transferase, theta 2
CTSH 94834_at cathepsin H
Continued, next pageToxicogenomics | Moggs et al.
1606 VOLUME 112 | NUMBER 16 | November 2004 • Environmental Health Perspectives
Appendix. Continued
Gene symbol Affymetrix Probe Set Gene description
UGT1A1 99580_s_at UDP glycosyltransferase 1 family, polypeptide A6
CD14 98088_at CD14 antigen
LGALS3 95706_at lectin, galactose binding, soluble 3
PGLYRP 104099_at peptidoglycan recognition protein
LGMN 93261_at legumain
GARG16 100981_at interferon-induced protein with tetratricopeptide repeats
H2Q1 99378_f_at MHC beta-2-microglobulin
ISGFG3 103634_at interferon dependent positive acting transcription
factor 3 gamma
H2D1 101886_f_at histocompatibility 2, D region locus 1
LYZP 101753_s_at P lysozyme structural
LYZM 100611_at lysozyme M
MLGP85 101389_at scavenger receptor class B, member 2
H2D1 97540_f_at histocompatibility 2, D region locus 1
CD68 103016_s_at CD68 antigen
LY6A 93078_at lymphocyte antigen 6 complex, locus A
MX1 98417_at myxovirus (inﬂuenza virus) resistance 1
Figure 7C—Chemoattractant cytokines
MCP3 94761_at monocyte chemoattractant protein 3
MCP1 102736_at platelet-derived growth factor-inducible protein JE
EOTAXIN 92742_at small inducible cytokine a11
Figure 7D—Complement
CFI 99927_at complement component factor i
C3 93497_at complement component 3
CFH-related  92291_f_at complement component factor-related
C2 103673_at complement component 2 (within H-2S)
CFH-related 101853_f_at complement component factor h
C1QA 98562_at complement component 1, q subcomponent,
alpha polypeptide
C1QB 96020_at complement component 1, q subcomponent,
beta polypeptide
C4 103033_at complement component 4 (within H-2S)
C1QC 92223_at complement component 1, q subcomponent, c polypeptide
CFH-related 94743_f_at complement component factor-related
Figure 7E—Iron homeostasis
CP 92851_at ceruloplasmin
LTF 101115_at lactotransferrin
LCN2 160564_at lipocalin 2/24p3 gene.
Figure 8B
ETS2 94246_at E26 avian leukemia oncogene 2, 3’ domain
ATF3 104155_f_at activating transcription factor 3
JUN 100130_at Jun oncogene
JUNB 102362_i_at transcription factor junB
FOS 160901_at c-fos oncogene
FOSB 103990_at FBJ osteosarcoma oncogene B
ATF5 103006_at activating transcription factor 5
ATF4 100599_at activating transcription factor 4
SPRR2I 95794_f_at small proline-rich protein 2I
SPRR2C 101761_f_at small proline-rich protein 2C
SPRR2G 101754_f_at small proline-rich protein 2G
SPRR2J 101755_f_at small proline-rich protein 2J
SPRR2A 101025_f_at small proline-rich protein 2A
SPRR2F 94120_s_at small proline-rich protein 2F
SPRR2E 100723_f_at small proline-rich protein 2E
SPRR1A 160909_at small proline-rich protein 1A
aGene annotations were derived by interrogation of the NetAffx (Liu et al. 2003) database; http://www.affymetrix.com/analysis/index.affx and by homology searching of nucleotide
sequence databases (BLASTn; http://www.ncbi.nih.gov/BLAST/) using Affymetrix probe target sequences.